ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September

September 7, 2021 GMT

NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences:

  • Morgan Stanley 19th Annual Global Healthcare Conference, September 9 – 10 and 13 – 15, 2021
    Fireside Chat: September 10, 8:45am ET

  • H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021
    Presentation: September 13, 7:00am ET

  • 2021 Cantor Virtual Global Healthcare Conference, September 27 – 30, 2021
    Presentation: September 28, 8:00-8:30am ET in Track 7

Webcasts will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. Archived replays will be accessible for 30 days following each event.

ADVERTISEMENT

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells and antibodies, the body’s natural infection killers, to fight or prevent serious disease.

HOOKIPA is developing a broad pipeline of potential first-in-class arenaviral immunotherapies in oncology and infectious disease. We are leveraging our proprietary, versatile platform to engineer arenaviral therapeutics that induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies to a broad range of self and non-self antigens, including viral antigens, tumor-associated antigens and neoantigens. Our immunotherapies are designed to use either non-replicating or replicating viral vectors based on the target disease, with the potential to induce CD8+ T cell response levels previously not achieved by other immunotherapy approaches.

HOOKIPA’s pipeline includes ongoing clinical trials in Human Papilloma Virus 16-positive cancers and Cytomegalovirus, as well as preclinical research in prostate cancer, HIV and Hepatitis B. The latter two are in collaboration with Gilead Sciences, Inc.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact: 
  
MediaInvestors
Astrid van ErvenMatt Beck
Senior Manager - CommunicationsExecutive Director - Investor Relations
astrid.vanerven@hookipapharma.commatthew.beck@hookipapharma.com